UroGen Pharma/$URGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About UroGen Pharma
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Ticker
$URGN
Sector
Primary listing
Employees
253
Headquarters
Website
UroGen Pharma Metrics
BasicAdvanced
$891M
-
-$3.28
1.13
-
Price and volume
Market cap
$891M
Beta
1.13
52-week high
$21.71
52-week low
$3.42
Average daily volume
1.2M
Financial strength
Current ratio
4.14
Quick ratio
3.714
Long term debt to equity
-134.854
Total debt to equity
-136.512
Interest coverage (TTM)
-8.27%
Profitability
EBITDA (TTM)
-122.177
Gross margin (TTM)
88.54%
Net profit margin (TTM)
-164.44%
Operating margin (TTM)
-129.95%
Effective tax rate (TTM)
-2.75%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-31.21%
Return on equity (TTM)
491.48%
Valuation
Price to revenue (TTM)
9.657
Price to book
-9.52
Price to tangible book (TTM)
-9.52
Price to free cash flow (TTM)
-7.367
Free cash flow yield (TTM)
-13.57%
Free cash flow per share (TTM)
-2.613
Growth
Revenue change (TTM)
10.85%
Earnings per share change (TTM)
5.46%
3-year revenue growth (CAGR)
17.77%
3-year earnings per share growth (CAGR)
-13.40%
What the Analysts think about UroGen Pharma
Analyst ratings (Buy, Hold, Sell) for UroGen Pharma stock.
Bulls say / Bears say
The FDA approved Zusduri™, UroGen’s gel-based mitomycin formulation for recurrent low-grade non-muscle invasive bladder cancer, on June 12, 2025. This approval provides a non-surgical treatment for an estimated 82,000 U.S. patients per year and marks UroGen’s move to a multi-product uro-oncology company.
In Q2 2025, UroGen reported Jelmyto net product revenues of $24.2 million, up 11% year-over-year due to stronger demand and favorable pricing. Results exceeded analyst expectations, showing significant commercial progress.
UroGen completed enrollment in its Phase 3 UTOPIA trial of UGN-103 on July 7, 2025, advancing its next-generation RTGel-based mitomycin candidate towards potential approval and demonstrating a robust product pipeline.
UroGen is facing a securities class action lawsuit alleging it misled investors regarding its FDA communications and dependence on a single-arm trial for UGN-102, which exposes the company to legal risks and potential reputational harm.
UroGen’s net loss increased to $49.9 million (−$1.05 per share) in Q2 2025, compared to a $33.4 million loss the previous year, mainly due to higher R&D and SG&A expenses from new product launches, which could impact future profitability.
On June 30, 2025, UroGen reported $161.6 million in cash and marketable securities, but its 2025 operating expense guidance stands at $215–225 million and it carries $247.3 million in combined long-term debt and RTW liabilities, suggesting possible liquidity pressures and risk of dilution.
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
UroGen Pharma Financial Performance
Revenues and expenses
UroGen Pharma Earnings Performance
Company profitability
UroGen Pharma News
AllArticlesVideos
3 Bullish Biotech Stocks With Explosive Growth Trends
MarketBeat2 months ago
URGN SHAREHOLDER ALERT: BFA Law Reminds UroGen Pharma Ltd. Investors of Upcoming July 28 Class Action Deadline - Contact The Firm if You Suffered Losses
Accesswire3 months ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines - URGN
Accesswire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for UroGen Pharma stock?
UroGen Pharma (URGN) has a market cap of $891M as of September 13, 2025.
What is the P/E ratio for UroGen Pharma stock?
The price to earnings (P/E) ratio for UroGen Pharma (URGN) stock is 0 as of September 13, 2025.
Does UroGen Pharma stock pay dividends?
No, UroGen Pharma (URGN) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next UroGen Pharma dividend payment date?
UroGen Pharma (URGN) stock does not pay dividends to its shareholders.
What is the beta indicator for UroGen Pharma?
UroGen Pharma (URGN) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.